-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Chemed, Raises Price Target to $675

Benzinga·10/29/2026 16:21:59
Listen to the news
UBS analyst A.J. Rice maintains Chemed (NYSE:CHE) with a Buy and raises the price target from $650 to $675.